|
|
Volumn 347, Issue , 2013, Pages f6696-
|
|
Johnson & Johnson to pay $2.2bn to settle charges of false marketing on three drugs
a
a
BMJ
*
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BRAIN NATRIURETIC PEPTIDE;
ISOXAZOLE DERIVATIVE;
PALIPERIDONE;
PYRIMIDINE DERIVATIVE;
RISPERIDONE;
DRUG INDUSTRY;
ECONOMICS;
FOOD AND DRUG ADMINISTRATION;
FRAUD;
HUMAN;
LEGISLATION AND JURISPRUDENCE;
MARKETING;
PRODUCT SAFETY;
UNITED STATES;
CONSUMER PRODUCT SAFETY;
DRUG INDUSTRY;
FRAUD;
HUMANS;
ISOXAZOLES;
MARKETING;
NATRIURETIC PEPTIDE, BRAIN;
PYRIMIDINES;
RISPERIDONE;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84891589065
PISSN: None
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.f6696 Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|